Kazia Therapeutics Annual Report 2021

KEY MILESTONES AND HIGHLIGHTS – 2020/2021 August 2020 Paxalisib is granted Rare Pediatric Disease Designation (RPDD) by the US FDA for DIPG and diffuse midline gliomas, making it eligible for a Pediatric Priority Review Voucher (PRV) if the drug is approved in this indication. August 2020 Paxalisib is granted Fast Track Designation (FTD) by the US FDA for glioblastoma, permitting enhanced consultation with FDA and access to ‘rolling review’ NDA submission. September 2020 Kazia enters into a partnership with Dana Farber Cancer Institute in Boston, MA to explore paxalisib in a phase II clinical trial in primary CNS lymphoma. October 2020 Kazia raises AU$ 24 million via an accelerated non-renounceable rights offering. November 2020 New interim data from paxalisib phase II study in glioblastoma directionally confirms earlier data and continues to suggest a survival benefit associated with the drug. December 2020 Kazia enters into a partnership with the Pacific Pediatric Neuro- Oncology Consortium (PNOC) to explore paxalisib in an international phase II combination trial in DIPG and diffuse midline gliomas. Kazia Therapeutics Limited 8 Annual Report 2021